Serbian startup Apotekamo raises 2.5 million euros to expand!

August 16, 2022 by
Frank Calviño

Apotekamo, a Serbian online pharmacy solution, has managed to raise 2.5 million euros in funding. The company will use this funding to expand into new markets, increase its marketing activities and finetune the platform’s logistics solution. Apotekamo aims at becoming the leading pharmacy in Southeast Europe.

Do you want to know more about international commerce and e-commerce, and also get all the tips and news that might give your company an edge? Subscribe to Cross-Border Magazine and get your digital copy now for free!

This e-company was originally founded in Serbia to offer over-the-counter and prescription drugs online, as well as digital services for third-party suppliers such as order processing and payment solutions. The company is mainly active in South-Eastern Europe and has become part of Swedish venture builder EPTI.

Apotekamo expansion plans

With 2.5 million euros raised and a pre-money valuation of 14.6 million euros, Apotekamo plans on using all its capital to expand in Southeast Europe. 

Currently, the company has begun expanding into Bosnia and Herzegovina, at the start of 2022, after acquiring a local pharmacy.  

New shareholder

Due to the investment raised,, FC Bayern Munich’s Sporting Director and former football player Hasan Salihamidžić has become the third largest shareholder of Apotekamo and will be part of the company’s marketing activities.

Mr. Srdjan Milic, CEO of Apotekamo said in this regard: “We are delighted with the trust from existing and new investors, especially given the current market climate and the geopolitical situation.”

A massive increase in orders for Apotekamo

This online pharmacy has seen its order intake increase by a massive 740% during the first half of 2022 compared to the same period last year. Something that could possibly be interpreted as a part of the global trend of increased use of e-commerce solutions for groceries, pharmaceutical, health, and well-being products, in the past two years. 

Top crossmenu

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.